Using Wearable Devices for Continuous Data Collection in Decentralized Clinical Trials

Wearable devices have become a cornerstone of modern GMP compliance in decentralized clinical trials (DCTs). These smart technologies allow for passive, continuous data collection from participants without requiring frequent clinic visits. From heart rate to blood oxygen levels and sleep patterns, wearables offer a scalable way to monitor trial participants in real time while supporting regulatory compliance and enhancing patient engagement. In this tutorial, we explore the types of wearable devices used in clinical trials, how they support data integrity, and best practices for implementation in DCTs.

What Are Wearable Devices in Clinical Trials?

Wearable devices are sensor-based, body-worn tools that track physiological metrics in real time or at set intervals. These devices often connect via Bluetooth or Wi-Fi and transmit data to centralized Electronic Data Capture (EDC) or cloud systems, enabling remote patient monitoring (RPM).

Key Metrics Captured by Wearables:

• Heart rate and heart rate variability (HRV)
• Electrocardiogram (ECG)
• Oxygen saturation (SpO₂)
• Respiratory rate
• Activity level and steps
• Sleep duration and quality
• Body temperature
• Blood glucose (in specialized continuous glucose monitors)

Popular Wearable Devices in Clinical Research:

• Fitbit: Used for tracking activity, sleep, and heart rate
• Apple Watch: Equipped with ECG and oxygen sensors
• Oura Ring: Detects sleep, temperature, and recovery
• BioIntelliSense BioSticker: Offers continuous multi-vital monitoring
• GlucoTrack and Dexcom: Monitor blood glucose non-invasively

Benefits of Wearable Data in DCTs:

1. Continuous Monitoring: Allows 24/7 data capture, identifying trends and anomalies
2. Improved Patient Experience: Reduces need for site visits and increases convenience
3. Real-Time Alerts: Enables immediate response to safety concerns
4. Objective Measurements: Enhances data reliability over self-reported outcomes
5. Protocol Compliance: Automatically logs and timestamps activities

Integration with Remote Monitoring Plans:

Wearables must be integrated into the trial’s Remote Patient Monitoring (RPM) plan, specifying:

• Type of device used and target metrics
• Data collection intervals
• Method of data transmission (e.g., app, cloud, EDC)
• Alert thresholds and escalation plans

This integration aligns with real-time stability studies and modern decentralized data models.

Data Flow and Validation Process:

To maintain data integrity and regulatory compliance, follow these steps:

• Ensure device is pre-validated and documented in the validation master plan
• Perform IQ/OQ/PQ on associated data platforms
• Capture data in a 21 CFR Part 11-compliant eSource platform
• Use audit trails and automated backup systems

Ensuring Participant Compliance and Training:

Wearables are only effective if participants use them consistently. Include the following in your plan:

• Clear instructions with visuals and videos
• Multilingual help resources and technical support
• Use of gamification or reminders to improve adherence
• Regular compliance tracking via apps or SMS

Regulatory Considerations:

Regulatory agencies like the EMA and TGA encourage innovation in DCTs but require robust evidence of device accuracy, calibration, and reliability. Include:

• Device manuals and validation data in submission dossiers
• Information on data handling, encryption, and cloud security
• Monitoring SOPs that reference device usage

Challenges and How to Overcome Them:

Best Practices for Trial Success:

• Select devices based on protocol endpoints and population demographics
• Pilot test wearables in a pre-trial phase
• Establish SOPs and contingency plans for device-related deviations
• Incorporate wearable data into centralized monitoring dashboards
• Align device data timelines with other clinical data sources

Case Study: Respiratory Clinical Trial Using BioSticker

A US-based respiratory study used BioIntelliSense BioSticker to continuously monitor respiratory rate, temperature, and activity. The data was integrated with an eSource platform and cross-validated with site assessments. The wearable detected early signs of exacerbations, allowing intervention before hospitalization. The use of AI and data analytics flagged high-risk participants, leading to improved outcomes and positive feedback from pharma regulatory requirements.

Conclusion:

Wearable devices have revolutionized continuous data collection in decentralized clinical trials. When properly selected, validated, and integrated into monitoring plans, wearables offer a seamless way to enhance patient safety, improve protocol compliance, and streamline data acquisition. As DCTs evolve, wearable technologies will remain critical in driving innovation, improving participant engagement, and meeting the expectations of global regulatory agencies.

Key Technologies Powering Remote Monitoring in Decentralized Clinical Trials

As clinical research continues to shift toward participant-centric models, Decentralized Clinical Trials (DCTs) are becoming more prevalent. A cornerstone of DCTs is remote patient monitoring (RPM), which uses digital technologies to collect trial data without requiring participants to visit clinical sites frequently. Leveraging advancements in telehealth, wearable sensors, mobile apps, and artificial intelligence, sponsors and CROs can now conduct trials that are more efficient, compliant, and accessible. In this tutorial, we’ll explore the major technologies enabling remote monitoring in DCTs and how to implement them effectively.

Why Remote Monitoring Matters in DCTs:

• Reduces participant burden and dropout rates
• Facilitates real-time data collection
• Improves access to underserved populations
• Enables flexible, site-less clinical trial designs
• Enhances safety oversight and protocol adherence

Core Technologies Enabling Remote Monitoring:

1. Wearable Devices and Biosensors

Wearables are used to collect vital signs such as heart rate, oxygen saturation, sleep quality, temperature, and activity levels. These FDA-cleared devices transmit real-time data to centralized dashboards, supporting early detection of safety events and protocol deviations.

• Examples: Fitbit, Apple Watch, BioIntelliSense BioSticker, Oura Ring
• Compliance tip: Ensure device calibration aligns with GMP validation principles

2. ePRO and eCOA Tools

Electronic Patient-Reported Outcomes (ePRO) and Clinical Outcome Assessment (eCOA) platforms allow patients to log symptoms, medication adherence, and quality-of-life data using mobile apps or web portals.

• Examples: Medidata eCOA, Veeva ePRO, TrialMax
• Built-in compliance features include timestamps, reminders, and audit trails

3. Telemedicine and Virtual Visits

Telehealth platforms facilitate remote interactions between investigators and participants. These video visits are useful for eligibility screening, safety assessments, and medication counseling.

• Ensure platforms are HIPAA and GDPR compliant
• Consent forms can be integrated via eConsent systems

4. Connected Drug Delivery Systems

Smart injectors and pill dispensers track dose administration in real-time and send alerts for missed doses. These technologies help maintain protocol compliance and adherence metrics.

• Examples: Hero Pill Dispenser, Insulet Omnipod, Propeller Health

5. eSource and EDC Platforms

Electronic Source (eSource) systems directly capture data from patients, devices, or clinician input and integrate with Electronic Data Capture (EDC) platforms. This ensures timely data flow for centralized monitoring.

• Examples: Medrio, OpenClinica, Castor
• Consider compatibility with Stability indicating methods when monitoring biological endpoints remotely

Integrating AI and Analytics into Remote Monitoring:

• Machine learning models can flag adverse events by analyzing incoming wearable and ePRO data
• Predictive analytics can identify high-risk patients for proactive intervention
• Natural language processing (NLP) enhances interpretation of unstructured patient-reported outcomes

Challenges in Implementing Remote Monitoring:

Regulatory Considerations for RPM in DCTs:

Agencies like the USFDA and EMA have provided draft guidance supporting remote assessments. However, sponsors must demonstrate that data collected remotely is equivalent in quality and reliability to on-site evaluations.

• Follow ICH E6(R3) GCP guidelines for remote data handling
• Document validation of each device or platform used
• Submit ePRO/eCOA system descriptions in clinical trial dossiers

Best Practices for Deploying Remote Monitoring in DCTs:

1. Conduct feasibility analysis of RPM tools during trial design phase
2. Include RPM training modules for participants and site staff
3. Integrate RPM with your Pharma SOP documentation
4. Pre-validate devices under protocol conditions
5. Plan contingency workflows for internet or device failure

Case Study:

A global dermatology DCT deployed wearable patches for remote skin monitoring and used ePRO apps for capturing flare-ups. The integration of wearable and app data into the sponsor’s EDC allowed for real-time safety monitoring. As per Health Canada expectations, system validation and audit logs ensured trial integrity during inspection.

Conclusion:

Remote monitoring technologies have transformed how clinical trials are designed and executed. By leveraging wearable devices, mobile platforms, and AI-powered analytics, sponsors can decentralize data collection without compromising quality. Careful planning, validated systems, and regulatory foresight are essential to harness the full potential of RPM in DCTs. These innovations not only ensure GCP compliance but also enhance participant engagement and trial outcomes in the modern research era.